이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Innovative Pharmaceutical Biotech 미래 성장

Future 기준 확인 0/6

현재 Innovative Pharmaceutical Biotech 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Trade Distributors 수익 성장	20.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Innovative Pharmaceutical Biotech 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:399 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	7	103	N/A	N/A	N/A
12/31/2023	7	84	N/A	N/A	N/A
9/30/2023	8	64	-19	-19	N/A
6/30/2023	8	-91	-18	-18	N/A
3/31/2023	8	-246	-18	-18	N/A
12/31/2022	8	-220	-9	-9	N/A
9/30/2022	9	-195	0	0	N/A
6/30/2022	10	-75	-6	-6	N/A
3/31/2022	11	46	-12	-12	N/A
12/31/2021	13	30	-21	-21	N/A
9/30/2021	15	14	-31	-31	N/A
6/30/2021	15	-96	-28	-28	N/A
3/31/2021	15	-205	-25	-25	N/A
12/31/2020	13	-200	-28	-28	N/A
9/30/2020	11	-194	-32	-32	N/A
6/30/2020	13	-203	-34	-34	N/A
3/31/2020	15	-211	-36	-36	N/A
12/31/2019	17	-205	-41	-41	N/A
9/30/2019	20	-199	-45	-45	N/A
6/30/2019	19	-230	-37	-37	N/A
3/31/2019	19	-260	-29	-29	N/A
12/31/2018	17	-258	3	3	N/A
9/30/2018	16	-256	35	35	N/A
6/30/2018	16	-243	10	10	N/A
3/31/2018	16	-231	-15	-15	N/A
12/31/2017	14	-237	N/A	-17	N/A
9/30/2017	13	-243	N/A	-19	N/A
6/30/2017	11	-206	N/A	51	N/A
3/31/2017	9	-170	N/A	120	N/A
12/31/2016	10	-196	N/A	48	N/A
9/30/2016	11	-223	N/A	-24	N/A
6/30/2016	16	-230	N/A	-79	N/A
3/31/2016	20	-237	N/A	-133	N/A
12/31/2015	25	-214	N/A	-80	N/A
9/30/2015	31	-190	N/A	-26	N/A
6/30/2015	32	-321	N/A	-31	N/A
3/31/2015	34	-452	N/A	-36	N/A
9/30/2014	41	-891	N/A	-60	N/A
6/30/2014	39	-730	N/A	-64	N/A
3/31/2014	36	-569	N/A	-67	N/A
12/31/2013	31	-522	N/A	-51	N/A
9/30/2013	21	-298	N/A	-44	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 399 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 399 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 399 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 399 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 399 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 399 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Innovative Pharmaceutical Biotech 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견